Salina Gairhe

Salina Gairhe

Auto-generated profile, based on publicly available information

Salina Gairhe

Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD 20892

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SGSalina Gairhe
Salina Gairhe
KAKeytam Salem Awad
Keytam Salem Awad
EDEdward J. Dougherty
Edward J. Dougherty
GFGabriela A. Ferreyra
Gabriela A. Ferreyra
SWShuibang Wang
Shuibang Wang
RDRobert L Danner
Robert L Danner
Significance: Caveolin-1 (CAV1) loss-of-function mutations are a hereditary cause of pulmonary arterial hypertension (PAH), but wild-type CAV1 is also decreased in the vascular lesions of idiopathic and disease-associated PAH. Using human pulmonary artery endothelium, lung tissue, and serum from Cav1 −/− mice, as well as fibroblasts and serum from patients with CAV1 mutations, CAV1 deficiency produced a dysfunctional, PAH-like endothelial phenotype driven by an interferon-biased inflammatory response with constitutive STAT and AKT activation. Inhibiting JAK/STAT and PI3K/AKT reversed the aberrant endothelial phenotype of CAV1 loss and may similarly ameliorate pathologic vascular remodeling in PAH. Exogenous interferon alone reduced CAV1 expression and activated these same signaling pathways, suggesting that CAV1 insufficiency may contribute to the development of autoimmune and autoinflammatory disease-associated PAH.